Zobrazeno 1 - 10
of 24
pro vyhledávání: '"N M Tikhanovskaya"'
Autor:
O I Kit, L Y Vladimirova, N A Abramova, A E Storozhakova, I L Popova, N M Tikhanovskaya, A A Lyaynova, L A Ryadinskaya
Publikováno v:
Современная онкология, Vol 19, Iss 2, Pp 42-46 (2017)
The data of the efficacy and safety regorafenib in the treatment of 7 patients with metastatic colorectal cancer (mCRC) refractory to treatment with cytostatics and monoclonal antibodies - blockers EGFR and VEGF were analyzed. The maximum anti-tumor
Externí odkaz:
https://doaj.org/article/e022525b6858401aaef3c15fabbf6fb3
Autor:
L V Bolotina, L V Manziuk, V A Gorbunova, E I Kovalenko, G Z Mukhametshina, A I Khasanova, L Yu Vladimirova, I S Mitashok, E P Prokofyeva, I V Evstigneeva, I I Andreyashkina, N A Abramova, I L Popova, E V Karabina, A A Teterich, E A Gaysina, V A Chubenko, S V Limareva, N M Tikhanovskaya, A E Storozhakova, N Yu Samaneva, Ya V Svetitskaya, T A Snezhko, E A Kalabanova
Publikováno v:
Современная онкология, Vol 18, Iss 3, Pp 27-32 (2016)
The article shows the experience of eribulin application in actual clinical practice in Oncology institutions of the Russian Federation concerning metastatic breast cancer. We have analyzed the efficacy of the drug in case of different subtypes of th
Externí odkaz:
https://doaj.org/article/02544f99d49748aabf8218f99df2b907
Autor:
A. A. Lyanova, L. Yu. Vladimirova, E. P. Ulyanova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, M. A. Teplyakova, L. A. Ryadinskaya, I. A. Udalenkova, E. A. Kalabanova, S. N. Kabanov
Publikováno v:
Южно-Российский онкологический журнал, Vol 3, Iss 4, Pp 40-48 (2022)
Purpose of the study. An analysis of changes in the expression of the VEGF neoangiogenic factor in the tumor tissue of patients with squamous cell carcinoma of the oral mucosa receiving targeted therapy with cetuximab and chemotherapy.Patients and me
Externí odkaz:
https://doaj.org/article/aaad8131f37d45919c047248caac54d3
Autor:
L. Yu. Vladimirova, E. M. Frantsiyants, N. A. Abramova, K. A. Novoselova, V. S. Myagkova, O. V. Katelnitskaya, A. E. Storozhakova, I. L. Popova, S. N. Kabanov, N. M. Tikhanovskaya, E. A. Kalabanova, L. A. Ryadinskaya, A. A. Lyanova, M. A. Teplyakova, V. R. Zakharchenko, N. K. Guskova
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 9, Iss 3, Pp 25-38 (2022)
Purpose of the study. An analysis of parameters of the blood coagulation system in breast cancer patients after coronavirus disease.Materials and methods. 50 breast cancer patients were divided into groups: the main group included 30 patients after c
Externí odkaz:
https://doaj.org/article/11865fec689245e7beb91d9a5389d4d9
Autor:
O. I. Kit, L. Yu. Vladimirova, E. A. Kalabanova, A. E. Storozhakova, S. N. Kabanov, T. A. Snezhko, I. S. Mitashok, Ya. V. Svetitskaya, N. Yu. Samaneva, I. S. Kornilova, Yu. V. Przhedetskiy, V. V. Pozdnyakova, N. A. Abramova, I. L. Popova, N. M. Tikhanovskaya, A. A. Lyanova, K. A. Novoselova, L. A. Ryadinskaya
Publikováno v:
Сибирский онкологический журнал, Vol 20, Iss 2, Pp 85-92 (2021)
Background. Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The prognosis of the disease is largely determined by thebiological subtype of the tumor. Her2-posi
Externí odkaz:
https://doaj.org/article/37520b7ab3864c81a9d042b834977f6f
Autor:
L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, E. V. Verenikina, S. N. Kabanov, Ya. V. Svetitskaya, N. Yu. Samaneva, N. M. Tikhanovskaya, K. A. Novoselova, O. G. Selezneva, A. V. Tishina
Publikováno v:
Южно-Российский онкологический журнал, Vol 1, Iss 3, Pp 67-74 (2020)
Ovarian cancer is one of the most common cancers in women. Growth and extension of the tumor are associated with active neoangiogenesis regulated by vascular endothelial growth factor (VEGF). Bevacizumab decreases VEGF activity and inhibits the tumor
Externí odkaz:
https://doaj.org/article/763932498d0d422f939dd5d540dfdd16
Autor:
A. A. Lianova, L. Yu. Vladimirova, N. A. Abramova, M. A. Teplyakova, I. L. Popova, N. M. Tikhanovskaya, A. E. Storozhakova, L. A. Ryadinskaya, I. A. Udalenkova, E. A. Kalabanova, D. Trifanov
Publikováno v:
Medical alphabet. :28-34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a61c5618b9978cacc340e630dae89806
https://doi.org/10.33667/2078-5631-2022-31-28-34
https://doi.org/10.33667/2078-5631-2022-31-28-34
Autor:
L. Yu. Vladimirova, M. A. Teplyakova, I. L. Popova, N. A. Abramova, N. M. Tikhanovskaya, A. A. Lianova, A. E. Storozhakova, L. A. Ryadinskaya, S. N. Kabanov, E. A. Kalabanova, I. A. Udalenkova, D. Trifanov
Publikováno v:
Medical alphabet. :35-40
Although melanoma is one of the most immunogenic tumors, it has an ability to evade anti-tumor immune responses by exploiting tolerance mechanisms. The most extensively studied checkpoints represent cytotoxic T lymphocyte-associated protein‑4 (CTLA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::752c1d99226133df03d5a1a800181f07
https://doi.org/10.33667/2078-5631-2022-26-35-40
https://doi.org/10.33667/2078-5631-2022-26-35-40
Autor:
L. Yu. Vladimirova, N. A. Abramova, A. A. Lyanova, A. E. Storozhakova, I. L. Popova, M. A. Teplyakova, N. M. Tikhanovskaya, L. A. Ryadinskaya, E. A. Kalabanova, S. N. Kabanov, I. A. Udalenkova
Publikováno v:
Meditsinskiy sovet = Medical Council. :117-125
Introduction. Erythropoietin (EPO) application is a pathogenetic method for anemia correction in cancer patients.The purpose of study. Clinical evaluation of the efficacy and safety of Eralfon® (epoetin alpha) in treatment for anemia in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bea9fc1e3c00baa6c56854ff6297bb6a
https://doi.org/10.21518/2079-701x-2022-16-9-117-125
https://doi.org/10.21518/2079-701x-2022-16-9-117-125
Autor:
L. Yu. Vladimirova, I. L. Popova, N. A. Abramova, M. A. Teplyakova, N. M. Tikhanovskaya, A. A. Lianova, A. E. Storozhakova, L. A. Ryadinskaya, S. N. Kabanov, E. A. Kalabanova
Publikováno v:
Meditsinskiy sovet = Medical Council. :186-192
The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed approaches to the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::733e09b8081a8f610384f2d3cf715bf6
https://doi.org/10.21518/2079-701x-2022-16-9-186-192
https://doi.org/10.21518/2079-701x-2022-16-9-186-192